Wells Fargo & Company Issues Positive Forecast for Cooper Companies (NASDAQ:COO) Stock Price

Cooper Companies (NASDAQ:COO) had its price target upped by Wells Fargo & Company from $72.00 to $82.00 in a report published on Friday,Benzinga reports. The firm currently has an equal weight rating on the medical device company’s stock.

Other research analysts also recently issued research reports about the stock. Barclays assumed coverage on shares of Cooper Companies in a report on Monday, October 13th. They issued an “overweight” rating and a $85.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Cooper Companies from $66.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday. Mizuho set a $100.00 price objective on Cooper Companies and gave the stock an “outperform” rating in a research report on Friday. Stifel Nicolaus set a $95.00 target price on Cooper Companies and gave the company a “buy” rating in a research note on Friday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $100.00 price target (up from $94.00) on shares of Cooper Companies in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Cooper Companies presently has an average rating of “Moderate Buy” and a consensus price target of $90.31.

Cooper Companies Stock Up 5.7%

Shares of COO stock opened at $81.40 on Friday. The stock’s 50 day simple moving average is $72.29 and its 200 day simple moving average is $71.74. Cooper Companies has a twelve month low of $61.78 and a twelve month high of $101.53. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12. The company has a market capitalization of $16.18 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 1.89 and a beta of 1.05.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.11 by $0.04. Cooper Companies had a return on equity of 10.01% and a net margin of 9.16%.The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter last year, the company posted $1.04 earnings per share. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, research analysts predict that Cooper Companies will post 3.98 EPS for the current year.

Cooper Companies announced that its board has authorized a share repurchase program on Wednesday, September 17th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Transactions at Cooper Companies

In other news, Director Lawrence Erik Kurzius purchased 2,000 shares of the business’s stock in a transaction on Monday, September 29th. The stock was purchased at an average price of $68.39 per share, with a total value of $136,780.00. Following the acquisition, the director directly owned 5,777 shares in the company, valued at approximately $395,089.03. The trade was a 52.95% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 1.98% of the stock is owned by corporate insiders.

Institutional Trading of Cooper Companies

Institutional investors have recently modified their holdings of the company. Zions Bancorporation National Association UT acquired a new position in shares of Cooper Companies in the first quarter valued at $33,000. Bell Investment Advisors Inc boosted its stake in Cooper Companies by 106.3% during the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after buying an additional 219 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in Cooper Companies in the 1st quarter valued at $40,000. J.Safra Asset Management Corp increased its holdings in Cooper Companies by 204.8% in the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after buying an additional 340 shares during the period. Finally, CYBER HORNET ETFs LLC acquired a new position in shares of Cooper Companies in the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.